Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)

F DiPersio (1), HP Erba (2), RA Larson (3), SM Luger (4), KF Mangan (5), MS Tallman (6), JF Brill (7), G Vuagniaux (8), E Rouits (8), C Zanna (8), JM Sorensen (7).

Presented at ASCO 2014, Chicago, USA

(1) Washington University , St. Louis, USA

(2) University of Michigan, Ann Arbor, USA

(3) University of Chicago, USA

(4) University, of Pennsylvania, Philadelphia, USA

(5) Temple University, Philadelphia, USA

(6) Memorial Sloan, Kettering Cancer Center, New York, USA

(7) Ascenta Therapeutics, Malvern, USA

(8) Debiopharm International SA, Lausanne, Switzerland